Pluri Inc. (PluriStem Therapeutics Inc.) 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on August 6, 2008, covering events occurring on August 5, 2008. The registrant, PluriStem Therapeutics Inc., is a Nevada corporation headquartered in Haifa, Israel. The filing discloses the entry into a material definitive agreement regarding a private placement of securities.
Key Financial Metrics and Transaction Details
The filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Securities Issued: 1,391,304 shares of Common Stock and Warrants to purchase 695,652 shares.
- Common Stock Price: $1.15 per share.
- Warrant Exercise Price: $1.90 per share.
- Warrant Terms: Exercisable after six months for a period of five years.
- Placement Agent: Rodman & Renshaw, LLC.
- Agent Compensation: 6% of the gross purchase price of the Units plus warrants to purchase 83,478 shares at $1.44 per share.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the execution of securities purchase agreements with two investors. This transaction represents a dilution of existing shareholders through the issuance of new common stock and warrants. The closing of the transaction is scheduled to take place no later than August 8, 2008.
Outlook, Risks, and Management Commentary
The offering was conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-151761). The filing incorporates by reference the form of Warrant (Exhibit 4.1) and the Securities Purchase Agreement (Exhibit 10.1). No specific management commentary regarding future operational outlook, risks, or contingencies is provided in this specific 8-K text beyond the standard incorporation of legal exhibits.
Investor Verification Checklist
- Verify the final closing date and total gross proceeds received from the August 5, 2008 offering.
- Review the full text of the Warrant (Exhibit 4.1) for specific exercise conditions and potential dilution impacts.
- Confirm the updated share count and capitalization table post-closing.
- Assess the impact of the 6% placement fee and agent warrants on the net capital raised.